{
  "$schema": "folio-library-document/v1",
  "id": "10665-258516",
  "title": "WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection: module 10: testing providers",
  "variant": "pdf",
  "pages": 24,
  "tocSource": "inferred",
  "tocMethod": "contents",
  "toc": [
    {
      "level": 1,
      "title": "INTRODUCTION",
      "number": null,
      "page": 4,
      "pageLabel": "2",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-000-introduction"
    },
    {
      "level": 1,
      "title": "THE TESTING PROVIDERS MODULE",
      "number": null,
      "page": 6,
      "pageLabel": "4",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-001-the-testing-providers-module"
    },
    {
      "level": 2,
      "title": "Key messages: testing services in the context of PrEP",
      "number": null,
      "page": 6,
      "pageLabel": "4",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-002-key-messages-testing-services-in-the-context-of"
    },
    {
      "level": 2,
      "title": "HIV testing services",
      "number": null,
      "page": 8,
      "pageLabel": "6",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-003-hiv-testing-services"
    },
    {
      "level": 2,
      "title": "Kidney function monitoring",
      "number": null,
      "page": 13,
      "pageLabel": "11",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-004-kidney-function-monitoring"
    },
    {
      "level": 2,
      "title": "Hepatitis B testing",
      "number": null,
      "page": 13,
      "pageLabel": "11",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-005-hepatitis-b-testing"
    },
    {
      "level": 2,
      "title": "Hepatitis C testing",
      "number": null,
      "page": 14,
      "pageLabel": "12",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-006-hepatitis-c-testing"
    },
    {
      "level": 2,
      "title": "Pregnancy testing",
      "number": null,
      "page": 16,
      "pageLabel": "14",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-007-pregnancy-testing"
    },
    {
      "level": 2,
      "title": "Testing for sexually transmitted infections",
      "number": null,
      "page": 16,
      "pageLabel": "14",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-008-testing-for-sexually-transmitted-infections"
    },
    {
      "level": 2,
      "title": "Syphilis testing",
      "number": null,
      "page": 16,
      "pageLabel": "14",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-009-syphilis-testing"
    },
    {
      "level": 2,
      "title": "WHO prequalification assessment and tools for testing providers",
      "number": null,
      "page": 18,
      "pageLabel": "16",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-010-who-prequalification-assessment-and-tools-for-te"
    },
    {
      "level": 2,
      "title": "Pre-market assessment of in vitro diagnostics",
      "number": null,
      "page": 18,
      "pageLabel": "16",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-011-pre-market-assessment-of-in-vitro-diagnostics"
    },
    {
      "level": 2,
      "title": "Post-market surveillance of in vitro diagnostics",
      "number": null,
      "page": 18,
      "pageLabel": "16",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-012-post-market-surveillance-of-in-vitro-diagnostics"
    },
    {
      "level": 1,
      "title": "REFERENCES",
      "number": null,
      "page": 19,
      "pageLabel": "17",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-013-references"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 4,
      "labelStart": "a",
      "labelEnd": "2",
      "words": 1504,
      "summary": {
        "text": "The front matter of WHO's PrEP implementation tool, Module 10 for testing providers (July 2017), with the copyright and licence page, citation and disclaimers, abbreviations and the table of contents.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hepatitis testing",
          "heading": false
        },
        {
          "term": "testing providers",
          "heading": false
        },
        {
          "term": "creative commons",
          "heading": false
        },
        {
          "term": "vitro diagnostics",
          "heading": false
        },
        {
          "term": "testing services",
          "heading": false
        },
        {
          "term": "suggested citation",
          "heading": false
        },
        {
          "term": "licence",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        }
      ],
      "extract": "WHO IMPLEMENTATION TOOL FOR PRE-EXPOSURE PROPHYLAXIS (PrEP) OF HIV INFECTION TESTING PROVIDERS MODULE 10 JULY 2017 WHO/HIV/2017.30 © World Health Organization 2017 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy,",
      "extractCut": true,
      "blocks": [
        "library/10665-258516/blocks/prose-sec-front-matter",
        "library/10665-258516/blocks/figure-img-p001-1"
      ]
    },
    {
      "id": "sec-000-introduction",
      "number": null,
      "title": "INTRODUCTION",
      "level": 1,
      "pageStart": 4,
      "pageEnd": 6,
      "labelStart": "2",
      "labelEnd": "4",
      "words": 1186,
      "summary": {
        "text": "Introduces WHO's series of implementation modules on oral pre-exposure prophylaxis (PrEP), produced after the 2015 recommendation that PrEP be offered to people at substantial HIV risk. It stresses that PrEP should complement, not replace, condoms and harm reduction, that key populations may face barriers, and that the choice to use PrEP rests with the individual. It outlines the target audience, guiding principles based on public health and human rights, and summarises each module and supporting resources.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prep users",
          "heading": false
        },
        {
          "term": "prep services",
          "heading": false
        },
        {
          "term": "offering prep",
          "heading": false
        },
        {
          "term": "monitor prep",
          "heading": false
        },
        {
          "term": "implementing prep",
          "heading": false
        },
        {
          "term": "young people",
          "heading": false
        },
        {
          "term": "module",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": false
        }
      ],
      "extract": "Following the WHO recommendation in September 2015 that “oral pre-exposure prophylaxis (PrEP) should be offered as an additional prevention choice for people at substantial risk of HIV infection as part of combination HIV prevention approaches”, partners in countries expressed the need for practical advice on how to consider the introduction of PrEP and start implementation. In response, WHO has developed this",
      "extractCut": true
    },
    {
      "id": "sec-001-the-testing-providers-module",
      "number": null,
      "title": "THE TESTING PROVIDERS MODULE",
      "level": 1,
      "pageStart": 6,
      "pageEnd": 6,
      "labelStart": "4",
      "labelEnd": "4",
      "words": 160,
      "summary": {
        "text": "Explains that the testing providers module helps programme managers choose testing services for screening before and monitoring during PrEP, covering HIV, creatinine, hepatitis B and C, pregnancy and sexually transmitted infections. It restates WHO's strong recommendation that oral PrEP containing TDF be offered to people at substantial risk.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "testing",
          "heading": true
        },
        {
          "term": "prep",
          "heading": false
        },
        {
          "term": "module",
          "heading": true
        },
        {
          "term": "hepatitis virus",
          "heading": false
        },
        {
          "term": "testing services",
          "heading": false
        },
        {
          "term": "recommendation",
          "heading": false
        }
      ],
      "extract": "This module is designed to support national HIV programme managers and other decision-makers who have an interest in implementing pre-exposure prophylaxis (PrEP) and require guidance in selecting the relevant testing services, including appropriate screening of clients before PrEP is initiated and monitoring while taking PrEP. Information is provided on testing for HIV, creatinine, hepatitis B virus (HBV), hepatitis",
      "extractCut": true
    },
    {
      "id": "sec-002-key-messages-testing-services-in-the-context-of",
      "number": null,
      "title": "Key messages: testing services in the context of PrEP",
      "level": 2,
      "pageStart": 6,
      "pageEnd": 8,
      "labelStart": "4",
      "labelEnd": "6",
      "words": 699,
      "summary": {
        "text": "Summarises the key testing messages for PrEP: HIV testing before starting and every three months, plus suggested creatinine, hepatitis B and C, pregnancy and STI testing. A table sets out each test, its timing and setting, including the preference for nucleic acid tests for gonorrhoea and chlamydia and syndromic management where these are unavailable.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prep",
          "heading": true
        },
        {
          "term": "restarting prep",
          "heading": false
        },
        {
          "term": "starting prep",
          "heading": false
        },
        {
          "term": "testing services",
          "heading": true
        },
        {
          "term": "prep initiation",
          "heading": false
        },
        {
          "term": "district provincial",
          "heading": false
        },
        {
          "term": "during prep",
          "heading": false
        },
        {
          "term": "prep users",
          "heading": false
        }
      ],
      "extract": "Several testing services must be delivered before a person can start taking PrEP safely and effectively. Periodic retesting while a person is taking PrEP is also needed. (See Table 1 below for a summary of suggested testing services for individuals starting and taking PrEP.) Testing for HIV is required to rule out infection prior to initiating PrEP. Once an individual has been initiated on PrEP, HIV testing is",
      "extractCut": true
    },
    {
      "id": "sec-003-hiv-testing-services",
      "number": null,
      "title": "HIV testing services",
      "level": 2,
      "pageStart": 8,
      "pageEnd": 13,
      "labelStart": "6",
      "labelEnd": "11",
      "words": 1977,
      "summary": {
        "text": "Describes HIV testing services before and during PrEP, explaining why ruling HIV in or out matters and how national algorithms using rapid tests apply in high and low prevalence settings. It covers handling discrepant results, acute infection, testing levels and staff qualifications across the health system, with flow diagrams. It closes by discussing rare infections with drug-resistant HIV despite PrEP and the need for surveillance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv testing",
          "heading": true
        },
        {
          "term": "reactive serology",
          "heading": false
        },
        {
          "term": "testing services",
          "heading": true
        },
        {
          "term": "restarting prep",
          "heading": false
        },
        {
          "term": "third-line assays",
          "heading": false
        },
        {
          "term": "generation serology",
          "heading": false
        },
        {
          "term": "starting prep",
          "heading": false
        },
        {
          "term": "report hiv-inconclusive",
          "heading": false
        }
      ],
      "extract": "All people at substantial risk of HIV infection who could be eligible for PrEP should be offered HIV testing services. Prior to starting or restarting PrEP, it is critical to rule in or rule out HIV infection in order to: i) Identify and diagnose people with HIV; ii) Refer and link people with HIV to treatment and care as early as possible; iii) Ensure people who have HIV do not start PrEP (3–5). HIV testing",
      "extractCut": true
    },
    {
      "id": "sec-004-kidney-function-monitoring",
      "number": null,
      "title": "Kidney function monitoring",
      "level": 2,
      "pageStart": 13,
      "pageEnd": 13,
      "labelStart": "11",
      "labelEnd": "11",
      "words": 276,
      "summary": {
        "text": "Advises serum creatinine testing before PrEP and every six months in the first year, noting that TDF can cause a small, usually reversible fall in creatinine clearance. It identifies people needing closer monitoring and describes laboratory and point-of-care testing options.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "creatinine clearance",
          "heading": false
        },
        {
          "term": "estimated creatinine",
          "heading": false
        },
        {
          "term": "creatinine testing",
          "heading": false
        },
        {
          "term": "prep",
          "heading": false
        },
        {
          "term": "min",
          "heading": false
        },
        {
          "term": "kidney",
          "heading": true
        },
        {
          "term": "function",
          "heading": true
        },
        {
          "term": "serum",
          "heading": false
        }
      ],
      "extract": "Creatinine testing It is suggested that serum creatinine testing be done prior to PrEP initiation and throughout the first year (every six months) of taking PrEP. After the first year, testing could be conducted less frequently. The use of PrEP containing TDF is associated in some people with a small decrease in estimated creatinine clearance, which occurs within months after starting PrEP. Based on the available",
      "extractCut": true
    },
    {
      "id": "sec-005-hepatitis-b-testing",
      "number": null,
      "title": "Hepatitis B testing",
      "level": 2,
      "pageStart": 13,
      "pageEnd": 14,
      "labelStart": "11",
      "labelEnd": "12",
      "words": 247,
      "summary": {
        "text": "Recommends considering hepatitis B surface antigen screening for people starting or restarting PrEP, especially where HBV is common or vaccination coverage is low. It explains the benefits of screening and how TDF-based PrEP interacts with HBV treatment, including the risk of flare if PrEP is stopped.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "chronic hbv",
          "heading": false
        },
        {
          "term": "hbv infection",
          "heading": false
        },
        {
          "term": "hbv treatment",
          "heading": false
        },
        {
          "term": "active hbv",
          "heading": false
        },
        {
          "term": "prep containing",
          "heading": false
        },
        {
          "term": "hepatitis",
          "heading": true
        },
        {
          "term": "containing tdf",
          "heading": false
        }
      ],
      "extract": "Hepatitis B surface antigen (HBsAg) testing Screening for chronic HBV infection should be considered for people starting or restarting PrEP. Chronic HBV infection is defined as the persistence of HBsAg for more than six months. Assays for HBsAg may be conducted at the point of care or within a laboratory (see Fig. 5). Testing for HBsAg as a marker of chronic HBV infection is warranted, particularly where there is a",
      "extractCut": true
    },
    {
      "id": "sec-006-hepatitis-c-testing",
      "number": null,
      "title": "Hepatitis C testing",
      "level": 2,
      "pageStart": 14,
      "pageEnd": 16,
      "labelStart": "12",
      "labelEnd": "14",
      "words": 301,
      "summary": {
        "text": "Suggests hepatitis C testing for people who inject drugs and men who have sex with men before PrEP and yearly thereafter. It explains why antibody tests alone do not show current infection and presents an algorithm using HCV RNA or core antigen testing to confirm it.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hcv rna",
          "heading": false
        },
        {
          "term": "hcv infection",
          "heading": false
        },
        {
          "term": "current hcv",
          "heading": false
        },
        {
          "term": "hcv core",
          "heading": false
        },
        {
          "term": "active hcv",
          "heading": false
        },
        {
          "term": "anti-hcv",
          "heading": false
        },
        {
          "term": "hbv infection",
          "heading": false
        },
        {
          "term": "serological evidence",
          "heading": false
        }
      ],
      "extract": "Consideration could be given to testing for evidence of HCV infection in men who have sex with men and people who inject drugs prior to initiation of PrEP and every 12 months thereafter (23). Testing for evidence of HCV infection is typically conducted by using a serological assay to detect antibodies to HCV (anti-HCV). However, evidence of anti-HCV alone is not indicative of active HCV infection as 15–45% of HCV",
      "extractCut": true
    },
    {
      "id": "sec-007-pregnancy-testing",
      "number": null,
      "title": "Pregnancy testing",
      "level": 2,
      "pageStart": 16,
      "pageEnd": 16,
      "labelStart": "14",
      "labelEnd": "14",
      "words": 79,
      "summary": {
        "text": "Notes that pregnancy testing can be offered to women and transgender men with signs of pregnancy, that pregnancy raises HIV risk, and that PrEP can continue through pregnancy.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pregnancy",
          "heading": true
        },
        {
          "term": "chooses",
          "heading": false
        },
        {
          "term": "prep",
          "heading": false
        }
      ],
      "extract": "Testing for pregnancy can be offered to women (and transgender men) who have signs and symptoms of pregnancy and, where indicated, a referral made to antenatal services. Pregnancy is associated with a higher risk of acquiring HIV infection (28). The acquisition of HIV during pregnancy can result in higher rates of mother-to-child transmission. PrEP can be continued through pregnancy unless the woman chooses to stop.",
      "extractCut": true
    },
    {
      "id": "sec-008-testing-for-sexually-transmitted-infections",
      "number": null,
      "title": "Testing for sexually transmitted infections",
      "level": 2,
      "pageStart": 16,
      "pageEnd": 16,
      "labelStart": "14",
      "labelEnd": "14",
      "words": 58,
      "summary": {
        "text": "States that PrEP visits offer a chance for regular screening for syphilis, gonorrhoea and chlamydia in line with national guidelines.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "sti screening",
          "heading": false
        },
        {
          "term": "infections",
          "heading": true
        },
        {
          "term": "transmitted",
          "heading": true
        }
      ],
      "extract": "PrEP provides an opportunity for regular screening for common STIs, including syphilis, gonorrhoeae and chlamydial infections. Where possible, programmes should expand and implement relevant national guidelines on STI screening among people starting or taking PrEP. Additional guidance on STI screening can be found in the WHO manual Laboratory diagnosis of sexually transmitted infections, including human",
      "extractCut": true
    },
    {
      "id": "sec-009-syphilis-testing",
      "number": null,
      "title": "Syphilis testing",
      "level": 2,
      "pageStart": 16,
      "pageEnd": 18,
      "labelStart": "14",
      "labelEnd": "16",
      "words": 491,
      "summary": {
        "text": "Covers syphilis screening at PrEP start and every three to six months, describing treponemal and nontreponemal assays and example testing strategies. It also addresses gonorrhoea and chlamydia testing, preferring nucleic acid tests and syndromic treatment where these are not available.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "syphilis testing",
          "heading": true
        },
        {
          "term": "treponemal assays",
          "heading": false
        },
        {
          "term": "treponemal test",
          "heading": false
        },
        {
          "term": "restarting prep",
          "heading": false
        },
        {
          "term": "syphilis prevalence",
          "heading": false
        },
        {
          "term": "recommended syphilis",
          "heading": false
        },
        {
          "term": "prep users",
          "heading": false
        },
        {
          "term": "prep programmes",
          "heading": false
        }
      ],
      "extract": "People starting or restarting PrEP will likely benefit from syphilis screening and periodic retesting every three to six months while using PrEP. PrEP programmes should adhere to the relevant national testing procedures and guidelines as conducted within existing health services. Depending on which assays are available and utilized in a particular setting, different testing strategies for diagnosis of syphilis can",
      "extractCut": true
    },
    {
      "id": "sec-010-who-prequalification-assessment-and-tools-for-te",
      "number": null,
      "title": "WHO prequalification assessment and tools for testing providers",
      "level": 2,
      "pageStart": 18,
      "pageEnd": 18,
      "labelStart": "16",
      "labelEnd": "16",
      "words": 184,
      "summary": {
        "text": "Explains that in vitro diagnostics are classed by risk, with HIV and HBV assays scrutinised most, and that WHO independently reviews the quality, safety and performance of diagnostics sold in resource-limited settings because regulation is often weak.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pre-market assessment",
          "heading": false
        },
        {
          "term": "ivds",
          "heading": false
        },
        {
          "term": "prequalification",
          "heading": true
        },
        {
          "term": "incorrect",
          "heading": false
        },
        {
          "term": "vitro",
          "heading": false
        },
        {
          "term": "hbv",
          "heading": false
        }
      ],
      "extract": "Both before an assay is marketed and after it is on the market, its quality, safety and performance must be assured. In vitro diagnostic medical devices (IVDs) are classified by regulatory authorities according to the risk they may pose to public health and individual health, taking into account the potential outcomes and impact if the result is incorrect. Assays for HIV and HBV (and others) usually attract the",
      "extractCut": true
    },
    {
      "id": "sec-011-pre-market-assessment-of-in-vitro-diagnostics",
      "number": null,
      "title": "Pre-market assessment of in vitro diagnostics",
      "level": 2,
      "pageStart": 18,
      "pageEnd": 18,
      "labelStart": "16",
      "labelEnd": "16",
      "words": 89,
      "summary": {
        "text": "Lists the three parts of WHO prequalification assessment of diagnostics: dossier review, quality-management review with site inspection, and independent performance evaluation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prequalification",
          "heading": false
        },
        {
          "term": "ivd",
          "heading": false
        },
        {
          "term": "vitro",
          "heading": true
        }
      ],
      "extract": "WHO conducts the prequalification assessment of IVDs using a standardized procedure to determine if the products meet WHO prequalification requirements. The assessment consists of three key components: • review of safety, quality and performance of the IVD as presented in a product dossier prepared by the manufacturer; • desk review of the quality management systems applied during production, followed by a site",
      "extractCut": true
    },
    {
      "id": "sec-012-post-market-surveillance-of-in-vitro-diagnostics",
      "number": null,
      "title": "Post-market surveillance of in vitro diagnostics",
      "level": 2,
      "pageStart": 18,
      "pageEnd": 19,
      "labelStart": "16",
      "labelEnd": "17",
      "words": 146,
      "summary": {
        "text": "Describes WHO's post-market surveillance system for diagnostics, combining proactive lot verification testing and reactive reporting of problems, with links to guidance and the prequalified products list.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "post-market surveillance",
          "heading": true
        },
        {
          "term": "vitro",
          "heading": true
        },
        {
          "term": "problem",
          "heading": false
        },
        {
          "term": "ivds",
          "heading": false
        },
        {
          "term": "ivd",
          "heading": false
        }
      ],
      "extract": "Once a product is placed on the market, its quality, safety and performance must be monitored to ensure it continues to meet standards. WHO has established a system for post-market surveillance of IVDs that supplements the obligations of manufacturers, who must also conduct their own post-market evaluation activities. In this context, post-market surveillance consists of: • proactive post-market surveillance (to",
      "extractCut": true
    },
    {
      "id": "sec-013-references",
      "number": null,
      "title": "REFERENCES",
      "level": 1,
      "pageStart": 19,
      "pageEnd": 24,
      "labelStart": "17",
      "labelEnd": "22",
      "words": 7010,
      "summary": {
        "text": "The reference list for the PrEP testing providers module, citing mainly PrEP trials, HIV drug resistance studies and WHO testing guidelines, followed by WHO HIV department contact details.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "preexposure prophylaxis",
          "heading": false
        },
        {
          "term": "hiv preexposure",
          "heading": false
        },
        {
          "term": "pre-exposure prophylaxis",
          "heading": false
        },
        {
          "term": "disoproxil fumarate",
          "heading": false
        },
        {
          "term": "prophylaxis trial",
          "heading": false
        },
        {
          "term": "tenofovir disoproxil",
          "heading": false
        },
        {
          "term": "bitstream eng",
          "heading": false
        },
        {
          "term": "oral pre-exposure",
          "heading": false
        }
      ],
      "extract": "1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New England Journal of Medicine. 2010;363(27):2587-99. 2. Grant RM, Liegler T, Defechereux P, Kashuba AD, Taylor D, Abdel-Mohsen M, et al. Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. AIDS. 2015;29(3):331-7.",
      "extractCut": true
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 0,
        "items": []
      },
      "found_not_listed": {
        "count": 0,
        "items": []
      },
      "page_mismatch": {
        "count": 0,
        "items": []
      }
    },
    "figureSequenceGaps": [],
    "pageLabelConflicts": {
      "count": 0,
      "items": []
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "restarting prep",
      "heading": false
    },
    {
      "term": "starting prep",
      "heading": true
    },
    {
      "term": "prep services",
      "heading": true
    },
    {
      "term": "retesting prep",
      "heading": false
    },
    {
      "term": "oral prep",
      "heading": false
    },
    {
      "term": "prep users",
      "heading": false
    },
    {
      "term": "prep initiation",
      "heading": false
    },
    {
      "term": "among prep",
      "heading": false
    },
    {
      "term": "prep containing",
      "heading": false
    },
    {
      "term": "during prep",
      "heading": false
    },
    {
      "term": "start prep",
      "heading": false
    },
    {
      "term": "prep programmes",
      "heading": false
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": "a",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 2,
      "label": "b",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "1",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 4,
      "label": "2",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 5,
      "label": "3",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 6,
      "label": "4",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 7,
      "label": "5",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 8,
      "label": "6",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 9,
      "label": "7",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 10,
      "label": "8",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 11,
      "label": "9",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 12,
      "label": "10",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 13,
      "label": "11",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 14,
      "label": "12",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 15,
      "label": "13",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 16,
      "label": "14",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 17,
      "label": "15",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 18,
      "label": "16",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 19,
      "label": "17",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 20,
      "label": "18",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 21,
      "label": "19",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 22,
      "label": "20",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 23,
      "label": "21",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 24,
      "label": "22",
      "source": "pdf-labels",
      "confidence": 0.7
    }
  ],
  "figures": [
    {
      "kind": "table",
      "number": "1",
      "title": "SUMMARY OF TESTING SERVICES FOR STARTING AND MONITORING PREP",
      "page": 7,
      "pageLabel": "5",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "1",
      "title": "SUGGESTED HIV, STI AND HEPATITIS TESTING SERVICES WITH ASSAY FORMAT MENU AND STAFF QUALIFICATIONS (6)",
      "page": 8,
      "pageLabel": "6",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "2",
      "title": "TESTING STRATEGY1 FOR HIV DIAGNOSIS IN HIGH PREVALENCE SETTINGS",
      "page": 9,
      "pageLabel": "7",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "3",
      "title": "TESTING STRATEGY FOR HIV DIAGNOSIS IN LOW PREVALENCE SETTINGS",
      "page": 10,
      "pageLabel": "8",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "4",
      "title": "DETECTING HIV OVER THE NATURAL HISTORY OF INFECTION (6, 9)",
      "page": 12,
      "pageLabel": "10",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "5",
      "title": "SEROLOGY TESTING FOR CHRONIC HBV INFECTION",
      "page": 14,
      "pageLabel": "12",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "6",
      "title": "TESTING STRATEGY FOR DIAGNOSIS OF VIRAEMIC HCV INFECTION2",
      "page": 15,
      "pageLabel": "13",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "7",
      "title": "WHO INTERIM RECOMMENDED SYPHILIS TESTING AND TREATMENT STRATEGY FOR LOW SYPHILIS PREVALENCE SETTINGS (BELOW 5%), INCLUDING FOR PREGNANT WOMEN",
      "page": 17,
      "pageLabel": "15",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "8",
      "title": "WHO INTERIM RECOMMENDED SYPHILIS TESTING AND TREATMENT STRATEGY FOR HIGH SYPHILIS PREVALENCE SETTINGS (ABOVE 5%)",
      "page": 17,
      "pageLabel": "15",
      "confidence": 0.7,
      "evidence": [
        "in-sequence",
        "graphic"
      ]
    }
  ],
  "images": [
    {
      "id": "img-p001-1",
      "file": "images/img-p001-1.webp",
      "page": 1,
      "narratives": {
        "en": "Photograph of a health worker's gloved hands holding a labelled blood sample tube, with a young woman seated in the background.",
        "ar": "صورة فوتوغرافية ليدَي عامل صحي مرتديتين قفازين تمسكان بأنبوب عيّنة دم موسوم، وفي الخلفية شابة جالسة.",
        "zh": "照片：一名卫生工作者戴手套的双手拿着一支贴有标签的血样管，背景中坐着一名年轻女子。",
        "es": "Fotografía de las manos enguantadas de un trabajador sanitario que sostienen un tubo de muestra de sangre etiquetado, con una mujer joven sentada al fondo.",
        "fr": "Photographie des mains gantées d’un agent de santé tenant un tube de prélèvement sanguin étiqueté, avec une jeune femme assise à l’arrière-plan.",
        "ru": "Фотография рук медицинского работника в перчатках, держащих промаркированную пробирку с кровью; на заднем плане сидит молодая женщина."
      },
      "state": "draft"
    }
  ],
  "tables": [
    {
      "label": "Table 1",
      "caption": "TABLE 1. SUMMARY OF TESTING SERVICES FOR STARTING AND MONITORING PREP",
      "pages": [
        7
      ],
      "columns": [
        {
          "titles": "PATHOGEN / ANALYTE"
        },
        {
          "titles": "TESTING LOCATION"
        },
        {
          "titles": "TIMING AND FREQUENCY"
        }
      ],
      "rows": [
        [
          "HIV (HIV antibodies (anti-HIV))",
          "Community/outreach; Primary care; Laboratory (district/ provincial/ national)",
          "Prior to starting or restarting PrEP and every three months during PrEP use. Programmes can also consider testing at 1 month after starting PrEP."
        ],
        [
          "Creatinine",
          "Primary care; Laboratory (district/ provincial/ national)",
          "Consider testing prior to starting or restarting PrEP and consider every six months during PrEP use. Increasing testing frequency may be considered if there are comorbid conditions affecting renal function."
        ],
        [
          "HBV (Hepatitis B surface antigen (HBsAg))",
          "Community/outreach; Primary care; Laboratory (district/ provincial/ national)",
          "If HBsAg test is reactive, evaluate for HBV treatment indications based on WHO hepatitis B treatment guidelines. PrEP can be started before the result is available. For those being treated for chronic HBV, it is important to undertake further laboratory testing before PrEP is stopped to help with deciding how to monitor for HBV flares or how to continue treatment. If HBsAg is not detected, with no history of immunization, vaccinating against HBV can be considered."
        ],
        [
          "HCV (HCV antibodies (anti-HCV))",
          "Community/outreach; Primary care; Laboratory (district, provincial, national)",
          "Consider testing for HCV in certain populations, such as men who have sex with men and people who inject drugs, prior to PrEP initiation and annually thereafter."
        ],
        [
          "Pregnancy",
          "Community/outreach; Primary care; Laboratory (district, provincial)",
          "When clinically indicated, for example women who report missed menses or symptoms of pregnancy."
        ],
        [
          "Syphilis (treponemal antibodies) Syphilis (rapid plasma reagin titer)",
          "Community/outreach; Primary care; Laboratory (district, provincial)",
          "When starting PrEP, consider testing and every three to six months during PrEP use to check for active syphilis infection and to evaluate response to treatment. Pregnant women seeking or taking PrEP with a single reactive treponemal or nontreponemal test result should be started on treatment."
        ],
        [
          "Neisseria gonorrhoeae (GC) Chlamydia trachomatis (CT)",
          "Laboratory (district, provincial, national)",
          "Consider testing when starting PrEP and every three to six months during PrEP use. Use of nucleic acid testing (NAT) technologies is preferred for testing for gonorrhoeae and chlamydia. If NAT technologies are not available, probe for symptoms and look for signs of STIs and treat syndromically."
        ]
      ],
      "narratives": {
        "en": "Laboratory and point-of-care tests for people starting and using HIV pre-exposure prophylaxis (PrEP): for each pathogen or analyte (HIV, creatinine, hepatitis B and C, pregnancy, syphilis, gonorrhoea and chlamydia) the table gives where testing can be done and its timing and frequency.",
        "ar": "الاختبارات المختبرية واختبارات نقاط الرعاية للأشخاص الذين يبدؤون الوقاية قبل التعرض لفيروس العوز المناعي البشري أو يستخدمونها: يبيّن الجدول لكل عامل ممرض أو مادة مُحلَّلة (فيروس العوز المناعي البشري، والكرياتينين، والتهاب الكبد B وC، والحمل، والزهري، والسيلان والمتدثرة) مكان إجراء الاختبار وتوقيته وتواتره.",
        "zh": "开始和使用艾滋病毒暴露前预防（PrEP）人群的检测服务：表中针对每种病原体或检测指标（艾滋病毒、肌酐、乙肝和丙肝、妊娠、梅毒、淋病和衣原体）给出检测地点以及检测时间和频率。",
        "es": "Pruebas para las personas que inician y usan la profilaxis previa a la exposición (PrEP) al VIH: para cada patógeno o analito (VIH, creatinina, hepatitis B y C, embarazo, sífilis, gonorrea y clamidia) se indican el lugar donde puede realizarse la prueba y su momento y frecuencia.",
        "fr": "Tests destinés aux personnes qui commencent ou utilisent la prophylaxie préexposition (PrEP) du VIH : pour chaque agent pathogène ou analyte (VIH, créatinine, hépatites B et C, grossesse, syphilis, gonorrhée et chlamydia), le tableau indique le lieu où le test peut être réalisé ainsi que son calendrier et sa fréquence.",
        "ru": "Тестирование лиц, начинающих и применяющих доконтактную профилактику (ДКП) ВИЧ: для каждого возбудителя или аналита (ВИЧ, креатинин, гепатиты B и C, беременность, сифилис, гонорея и хламидиоз) указаны место проведения тестирования, его сроки и частота."
      },
      "csv": "tables/table-1.csv"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 14,
      "note": "inferred"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 15,
      "note": "2 levels"
    },
    {
      "kind": "figures",
      "state": "partial",
      "count": 1,
      "note": "8 captioned in the text"
    },
    {
      "kind": "tables",
      "state": "found",
      "count": 1
    },
    {
      "kind": "references",
      "state": "not-extracted",
      "note": "a references section is in the text (p19); its entries are not extracted"
    },
    {
      "kind": "glossary",
      "state": "none",
      "note": "no such heading in the text"
    },
    {
      "kind": "footnotes",
      "state": "not-extracted"
    },
    {
      "kind": "summaries",
      "state": "found",
      "count": 15,
      "note": "15 of 15 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-258516"
  }
}
